FindTrial
Sign In

Predicting head and neck cancer radiotherapy toxicity from clinical, imaging and radiotherapy dose data using heuristics and machine learning.

Hamlet.rt - Heuristics Algorithms and Machine Learning Evaluation & Testing In Radiation Therapy-India Specific Protocol. - HAMLET

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055496
Enrollment
100
Registered
2023-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C32- Malignant neoplasm of larynx Health Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: NIL: NIL

Sponsors

Tata Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with primary head and neck cancer Suitable for image-guided radiotherapy with curative intent Expected survival 18 months or more

Exclusion criteria

Exclusion criteria: Patients not willing or able to complete the protocol stated requirements of the study and completing web-based outcome and patient-reported outcomes measures.

Design outcomes

Primary

MeasureTime frame
Clinical toxicity by the CTCAEV3 criteria, & LENT SOMA criteria.Timepoint: end of treatment, 3, 6, 9, 12, 18, 24 months—

Secondary

MeasureTime frame
Patient reported outcome measures by EORTC head & neck and modified xerostomia questionnairesTimepoint: end of treatment, 3, 6, 9, 12, 18, 24 months;Treatment outcome by disease free & overall survivalTimepoint: 12 & 24 months—

Countries

India

Contacts

Public ContactDr Indranil Mallick

Tata Medical Center

indranil.mallick@tmckolkata.com9831171235

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026